Edition:
United States

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

2.85USD
14 Dec 2018
Change (% chg)

$-0.20 (-6.56%)
Prev Close
$3.05
Open
$3.05
Day's High
$3.05
Day's Low
$2.82
Volume
78,190
Avg. Vol
77,926
52-wk High
$3.92
52-wk Low
$1.12

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris Receives Positive CHMP Opinion On Macimorelin For Diagnosis Of Adult Growth Hormone Deficiency
Monday, 19 Nov 2018 08:00am EST 

Nov 19 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS (AEZS) RECEIVES POSITIVE CHMP OPINION OF MACIMORELIN FOR DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY.AETERNA ZENTARIS INC - RECOMMENDATION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION.  Full Article

Aeterna Zentaris Qtrly Loss Per Share $0.15
Tuesday, 6 Nov 2018 06:13pm EST 

Nov 6 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS REPORTS THIRD QUARTER 2018 FINANCIAL AND OPERATING RESULTS.QTRLY LOSS PER SHARE $0.15.Q3 REVENUE $663,000 VERSUS $241,000.  Full Article

Aeterna Zentaris Announces Novo Nordisk To Acquire Rights To Macrilen In U.S. And Canada
Thursday, 1 Nov 2018 08:00am EDT 

Nov 1 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES NOVO NORDISK TO ACQUIRE RIGHTS TO MACRILEN™ IN UNITED STATES AND CANADA.AETERNA ZENTARIS INC - NOVO NORDISK WILL ACQUIRE FROM STRONGBRIDGE BIOPHARMA PLC ITS RIGHTS TO MACRILEN IN UNITED STATES AND CANADA.AETERNA ZENTARIS INC - HAS LICENSED RIGHTS TO MACRILEN™ IN UNITED STATES AND CANADA TO STRONGBRIDGE BIOPHARMA.  Full Article

Aeterna Zentaris Qtrly Loss Per Share $0.03
Wednesday, 28 Mar 2018 07:00am EDT 

March 28 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATING RESULTS.AETERNA ZENTARIS INC - AT DECEMBER 31, 2017, WE HAD $7.8 MILLION OF CASH AND CASH EQUIVALENTS.AETERNA ZENTARIS- EXPECT EXISTING CASH BALANCES WILL PROVIDE WITH ADEQUATE FUNDS TO SUPPORT CURRENT OPERATING PLAN FOR AT LEAST NEXT TWELVE MONTHS.AETERNA ZENTARIS INC QTRLY LOSS PER SHARE $0.03.  Full Article

Strongbridge Announces Acquisition Of U.S., Canadian Rights To Macrilen From Aeterna Zentaris
Wednesday, 17 Jan 2018 07:00am EST 

Jan 17 (Reuters) - Strongbridge Biopharma Plc ::STRONGBRIDGE BIOPHARMA PLC ANNOUNCES ACQUISITION OF THE U.S. AND CANADIAN RIGHTS TO MACRILEN™ (MACIMORELIN) FROM AETERNA ZENTARIS.STRONGBRIDGE BIOPHARMA - ‍UNDER TERMS OF AGREEMENT, CO TO MAKE UPFRONT PAYMENT OF $24 MILLION TO AETERNA WITHIN 5 DAYS OF EFFECTIVE DATE OF AGREEMENT​.STRONGBRIDGE BIOPHARMA - LICENSE & ASSIGNMENT AGREEMENT ALSO PROVIDES CO WITH EXCLUSIVE LICENSE TO MANUFACTURE & COMMERCIALIZE MACRILEN IN U.S. & CANADA.STRONGBRIDGE BIOPHARMA PLC - STRONGBRIDGE EXPECTS TO COMMERCIALLY LAUNCH MACRILEN IN MID-YEAR 2018.STRONGBRIDGE BIOPHARMA PLC - ‍EXPANDS STRUCTURED FINANCING FACILITY WITH CRG TO SUPPORT ANTICIPATED COMMERCIAL LAUNCH OF MACRILEN IN MID-2018​.STRONGBRIDGE BIOPHARMA - AETERNA ZENTARIS WILL REMAIN RESPONSIBLE FOR A PEDIATRIC DEVELOPMENT PROGRAM TO SUPPORT REGULATORY SUBMISSION FOR MACRILEN APPROVAL.STRONGBRIDGE - ‍IN CONJUNCTION WITH MACRILEN DEAL, CO, CRG AMENDED EXISTING SENIOR CREDIT FACILITY TO INCREASE TOTAL POTENTIAL BORROWING TO $100 MILLION​.STRONGBRIDGE BIOPHARMA-CO SHARING OVERSIGHT AND PAYING FOR 70 PERCENT OF COST OF PEDIATRIC DEVELOPMENT PROGRAM OR ABOUT $4 MILLION OVER A 3-YEAR PERIOD​.STRONGBRIDGE - ‍UNDER AMENDED FACILITY, CO RETAINED OPTION TO BORROW ADDITIONAL $10 MILLION BASED UPON SOME CONDITIONS​.STRONGBRIDGE - ‍INTENDS TO USE UPFRONT PROCEEDS FROM SECOND BORROWING TO FUND ACQUISITON, COMMERCIALIZATION OF MACRILEN, CORPORATE PURPOSES​.  Full Article

Aeterna Zentaris Provides Update On Litigation Against David Dodd And Philip Theodore
Friday, 22 Dec 2017 04:15pm EST 

Dec 22 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS PROVIDES UPDATE ON LITIGATION AGAINST DAVID DODD AND PHILIP THEODORE.AETERNA ZENTARIS INC - CO AND ITS CHAIR CONSIDER COUNTERCLAIM AGAINST THEM TO BE "ENTIRELY WITHOUT MERIT".AETERNA ZENTARIS - IN RECEIPT OF A STATEMENT OF DEFENCE AND COUNTERCLAIM FILED BY FORMER OFFICERS DAVID DODD AND PHILIP THEODORE.AETERNA ZENTARIS - COUNTERCLAIM ALLEGES DEFAMATORY STATEMENTS IN RESPECT OF DODD, THEODORE WERE MADE IN A CO'S PRESS RELEASE & CLAIMS DAMAGES OF $6 MILLION.  Full Article

David Dodd And Philip Theodore Respond To Claim By Aeterna Zentaris
Thursday, 21 Dec 2017 04:01pm EST 

Dec 21 (Reuters) - Aeterna Zentaris Inc ::DAVID DODD AND PHILIP THEODORE RESPOND TO CLAIM BY AETERNA ZENTARIS.DAVID DODD - DODD, FORMER CEO OF AETERNA ZENTARIS & PHILIP THEODORE, CO'S FORMER GENERAL COUNSEL, HAVE RESPONDED TO CLAIM FILED AGAINST THEM BY CO.DAVID DODD SAYS DODD & PHILIP THEODORE HAVE BROUGHT A COUNTERCLAIM AGAINST CO & ITS CHAIR, CAROLYN EGBERT, IN AMOUNT OF $6.0 MILLION.DAVID DODD - DODD AND THEODORE HAVE BROUGHT COUNTERCLAIM AGAINST CO AND ITS CHAIR, CAROLYN EGBERT, IN AMOUNT OF $6.0 MILLION.  Full Article

Aeterna Zentaris Announces FDA Approval Of Macrilen For Diagnosis Of Adult Growth Hormone Deficiency
Wednesday, 20 Dec 2017 05:00pm EST 

Dec 20 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES FDA APPROVAL OF MACRILEN™ (MACIMORELIN) FOR DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY.AETERNA ZENTARIS - INTENDS TO MAKE MACRILEN AVAILABLE COMMERCIALLY IN UNITED STATES DURING Q1 OF 2018.  Full Article

Aeterna Zentaris Announces Departure Of Interim Chief Financial Officer
Friday, 8 Dec 2017 08:00am EST 

Dec 8 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES DEPARTURE OF INTERIM CHIEF FINANCIAL OFFICER.AETERNA ZENTARIS INC - DEPARTURE OF COMPANY'S INTERIM CHIEF FINANCIAL OFFICER, JEFFREY WHITNELL, EFFECTIVE DECEMBER 7, 2017.AETERNA ZENTARIS INC - COMMENCED A SEARCH FOR WHITNELL'S REPLACEMENT AS PRINCIPAL FINANCIAL OFFICER.  Full Article

Aeterna Zentaris’ MAA for Macrilen™ accepted by EMA
Monday, 27 Nov 2017 04:41pm EST 

Nov 27 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS’ MARKETING AUTHORIZATION APPLICATION FOR MACRILEN™ (MACIMORELIN) FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY ACCEPTED BY EUROPEAN MEDICINES AGENCY.AETERNA ZENTARIS INC - ‍MAA FOR USE OF MACRILEN FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY BEEN ACCEPTED BY EMA FOR REGULATORY REVIEW​.  Full Article